Alexza Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. The company s lead product candidate includes ADASUVE (Staccato loxapine) for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. Its other product candidates under development comprise AZ-007 (Staccato zaleplon), which has completed Phase I clinical trials for the treatment of insomnia; and Staccato nicotine that is in pre-Phase 1 clinical trials to help smokers quit by addressing both the chemical and behavioral components of nicotine addiction by delivering nicotine replacement through inhalation. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Mountain View, California.
Symbol:
Current Quote
last: 4.57
bid:
ask:
volume: 280635

as of (GMT): 2013-05-24 16:00:00
*Quotes delayed by 20min.
Stock Exchange / Market : NASDAQ
 Off list - 93 consecutive market days. Off list as of 11/30/2010 through 05/23/2013 

3 Month
ALXA 3 Month

6 Month
ALXA 6 Month

1 Year
ALXA 1 Year

Borrow Rates (per share)